Journal
JOURNAL OF IMMUNOLOGICAL METHODS
Volume 275, Issue 1-2, Pages 31-40Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0022-1759(02)00542-2
Keywords
anti-ICAM-1antibody; antibody humanization; CDR grafting; human rhinovirus
Categories
Funding
- NIAID NIH HHS [1 R43 AI50366-01] Funding Source: Medline
Ask authors/readers for more resources
The monoclonal antibody 1A6 binds to human intercellular adhesion molecule 1 (ICAM-1, CD54) and inhibits infection by 90% of human rhinovirus (HRV) serotypes. To make a therapeutic molecule for preventing and treating HRV infection, we humanized a single chain antibody (scFv), 1A6, by a structure-guided complementarity-determining region (CDR) grafting procedure. Our final humanized 1A6 scFv does not retain any mouse back mutations in the framework. Without changing the CDR sequences, the humanized 1A6 scFv demonstrates over 50-fold improvement in both affinity for ICAM-1 and protection efficacy against HRV infection in vitro. (C) 2002 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available